Abstract
The bacterial cell wall represents the primary target for antimicrobial agents. Microbial destruction is accompanied by the release of potent immunostimulatory membrane constituents. Both Gram-positive and Gram-negative bacteria release a variety of lipoproteins and peptidoglycan fragments. Gram-positive bacteria additionally provide lipoteichoic acids, whereas Gram-negative bacteria also release lipopolysaccharide (LPS, endotoxin), essential component of the outer leaflet of the bacterial cell wall and one of the most potent immunostimulatory molecules known. Immune activation therefore can be considered as an adverse effect of antimicrobial destruction and killing during anti-infective treatment. In contrast to antibiotics, the use of cationic amphiphilic antimicrobial peptides allows both effective bacterial killing and inhibition of the immunostimulatory effect of the released bacterial membrane constituents. The administration of antimicrobial peptides alone or in combination with antibiotic agents thus represents a novel strategy in the antiinfective treatment with potentially important beneficial aspects. Here, data are presented which describe immunological and clinical aspects of the use of antimicrobial peptides (AMPs) as therapeutic agents to treat bacterial infection and neutralize the immunostimulatory activity of released cell wall constituents.
Keywords: Antimicrobial agents, bacterial cell wall, Gram-negative bacteria, Gram-positive bacteria, lipopolysaccharide, antimicrobial peptides, immunostimulatory membrane, toll-like receptor, EGFR, Immune activation
Current Drug Targets
Title:Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Volume: 13 Issue: 9
Author(s): Tobias Schuerholz, Sabine Domming, Mathias Hornef, Aline Dupont, Ina Kowalski, Yani Kaconis, Lena Heinbockel, Jorg Andra, Patrick Garidel, Thomas Gutsmann, Sunil David, Susana Sanchez-Gomez, Guillermo Martinez de Tejada and Klaus Brandenburg
Affiliation:
Keywords: Antimicrobial agents, bacterial cell wall, Gram-negative bacteria, Gram-positive bacteria, lipopolysaccharide, antimicrobial peptides, immunostimulatory membrane, toll-like receptor, EGFR, Immune activation
Abstract: The bacterial cell wall represents the primary target for antimicrobial agents. Microbial destruction is accompanied by the release of potent immunostimulatory membrane constituents. Both Gram-positive and Gram-negative bacteria release a variety of lipoproteins and peptidoglycan fragments. Gram-positive bacteria additionally provide lipoteichoic acids, whereas Gram-negative bacteria also release lipopolysaccharide (LPS, endotoxin), essential component of the outer leaflet of the bacterial cell wall and one of the most potent immunostimulatory molecules known. Immune activation therefore can be considered as an adverse effect of antimicrobial destruction and killing during anti-infective treatment. In contrast to antibiotics, the use of cationic amphiphilic antimicrobial peptides allows both effective bacterial killing and inhibition of the immunostimulatory effect of the released bacterial membrane constituents. The administration of antimicrobial peptides alone or in combination with antibiotic agents thus represents a novel strategy in the antiinfective treatment with potentially important beneficial aspects. Here, data are presented which describe immunological and clinical aspects of the use of antimicrobial peptides (AMPs) as therapeutic agents to treat bacterial infection and neutralize the immunostimulatory activity of released cell wall constituents.
Export Options
About this article
Cite this article as:
Schuerholz Tobias, Domming Sabine, Hornef Mathias, Dupont Aline, Kowalski Ina, Kaconis Yani, Heinbockel Lena, Andra Jorg, Garidel Patrick, Gutsmann Thomas, David Sunil, Sanchez-Gomez Susana, Martinez de Tejada Guillermo and Brandenburg Klaus, Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects, Current Drug Targets 2012; 13 (9) . https://dx.doi.org/10.2174/138945012802002438
DOI https://dx.doi.org/10.2174/138945012802002438 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Different Inflammatory Biomarker Patterns in the Cerebro-Spinal Fluid Following Heart Surgery and Major Non-Cardiac Operations
Current Drug Metabolism Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Good at Heart: Preserving Cardiac Metabolism during aging
Current Diabetes Reviews Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Recent Applications of Grape Polyphenols in Foods, Beverages and Supplements
Recent Patents on Food, Nutrition & Agriculture Availability of Some Elements from Different Types of Teas
The Natural Products Journal Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Subject Index To Volume 6
Current Molecular Medicine Patent Ductus Arteriosus in the Preterm Infant: An Update on Morbidity and Mortality
Current Pediatric Reviews 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Matrix Metalloproteinases: A Potential Therapeutic Target in Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology